The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Updates from the IKEMA trial: Isa-Kd versus Kd in R/R multiple myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares some updates from the Phase III IKEMA trial (NCT03275285), which compared the safety and efficacy of isatuximab, carfilzomib and dexamethasone (Isa-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory (R/R) multiple myeloma, commenting on the overall response rate (ORR), depth of response, and progression-free survival (PFS) observed. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
